LY 2090314

Drug Profile

LY 2090314

Alternative Names: GSK3 inhibitor - Eli Lilly; LY2090314

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class 3-ring heterocyclic compounds; Antineoplastics; Maleimides; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • No development reported Acute myeloid leukaemia; Acute promyelocytic leukaemia

Most Recent Events

  • 25 Feb 2016 Eli Lilly terminates a phase I/II trial for Pancreatic cancer (metastatic disease) in USA (NCT01632306)
  • 08 Sep 2015 No recent reports on development identified - Phase-II for Acute myeloid leukaemia (Recurrent) and Acute promyelocytic leukaemia (Recurrent) in USA (IV)
  • 01 Mar 2013 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, First-line therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top